Frontiers in Public Health, Год журнала: 2023, Номер 11
Опубликована: Ноя. 22, 2023
DATA REPORT article Front. Public Health, 22 November 2023Sec. Infectious Diseases: Epidemiology and Prevention Volume 11 - 2023 | https://doi.org/10.3389/fpubh.2023.1271917
Язык: Английский
Frontiers in Veterinary Science, Год журнала: 2025, Номер 11
Опубликована: Янв. 3, 2025
Widespread surveillance for SARS-CoV-2 was conducted across wildlife, captive animals in zoological collections, and domestic cats Nebraska from 2021 to 2023. The goal of this effort determine the prevalence, phylogenetic spatial distribution characteristics circulating variants using various diagnostic methodologies that can utilize both antemortem postmortem samples, which may be required wildlife such as white-tailed deer. Statewide testing revealed high variation prevalence among species, with deer identified primary reservoir. In 2021, seroprevalence 63.73% (n = 91) 39.66% 237) 2022, while virus detection retropharyngeal lymph nodes (RLN) 16.35% 483) 3.61% 277) 2022. Phylogenetic analysis on 11 positive samples 2021. This presence four lineages Delta variant: AY.100, AY.119, AY.3, AY.46.4. Conversely, other species showed no detection, except cats, had a low 2.38% 628) indicating minimal exposure. identification multiple underscores need ongoing importance different methodologies. These efforts are critical understanding circulation evolution animals, informing public health strategies, mitigating risks zoonotic transmission emerging infectious diseases.
Язык: Английский
Процитировано
0
International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(5), С. 1898 - 1898
Опубликована: Фев. 22, 2025
Virus-induced antibodies represent a dual-edged sword in the immune response to viral infections. While are critical for neutralizing pathogens, some can paradoxically exacerbate disease severity through mechanisms such as antibody-dependent enhancement (ADE), autoantibody, and prolonged inflammation. Long coronavirus (COVID) dengue hemorrhagic fever (DHF) exemplify conditions where pathogenic play pivotal role progression. COVID is associated with persistent dysregulation autoantibody production, leading chronic symptoms tissue damage. In DHF, pre-existing against virus contribute ADE, amplifying replication, activation, vascular permeability. This review explores underlying these antibody responses, highlighting shared pathways of comparing distinct features both conditions. By examining studies, we identify key lessons therapeutic strategies, vaccine design, future research aimed at mitigating severe outcomes
Язык: Английский
Процитировано
0
Vaccines, Год журнала: 2024, Номер 12(1), С. 94 - 94
Опубликована: Янв. 18, 2024
The capability of antibodies to neutralize different SARS-CoV-2 variants varies among individuals depending on the previous exposure wild-type or Omicron-specific immunogens by mono- bivalent vaccinations infections. Such profiles neutralizing (nAbs) usually have be assessed via laborious live-virus neutralization tests (NTs). We therefore analyzed whether a novel multivariant surrogate-virus test (sVNT) (adapted from commercial microarray) that quantifies antibody-mediated inhibition between receptor angiotensin-converting enzyme 2 (ACE2) and variant-specific receptor-binding domains (RBDs) can assess activity against wild-type, Delta Omicron BA.1, BA.2, BA.5 subvariants after booster with Omicron-adapted vaccines in manner similar NTs. Indeed, using NTs as reference, we found significant correlation NT titers levels ACE2-RBD binding (p < 0.0001, r ≤ 0.78 respectively). Furthermore, sVNTs identified higher values BA.1 vaccinated than those monovalent vaccines. Our data thus demonstrate ability detect nAbs following
Язык: Английский
Процитировано
3
COVID, Год журнала: 2024, Номер 4(8), С. 1272 - 1290
Опубликована: Авг. 16, 2024
The emergence of COVID-19 has evolved into a global pandemic, causing an unprecedented public health crisis marked by levels morbidity never seen in the recent past. Considerable research efforts have been made scientific community to establish optimal method identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and understand induced immune response. This review examined development serological tests during considering factors affecting sensitivity specificity, which are key promote efficient vaccination strategy for health. market witnessed introduction various detection SARS-CoV-2, such as chemiluminescence immunoassay (CLIA), emerged powerful rapid tool monitor antibody response before after or infection. Therefore, developing studying trends persistence is essential creating long-term strategies. Our analysis underscores multifaceted applications pandemic management with focus on critical insights they provide dynamics that help managing ongoing shaping future initiatives, providing basis optimizing viral threats.
Язык: Английский
Процитировано
3
Vaccines, Год журнала: 2024, Номер 12(8), С. 914 - 914
Опубликована: Авг. 13, 2024
Since the initiation of COVID-19 pandemic, there has been a need for development diagnostic methods to determine factors implicated in mounting an immune response against virus. The most promising indicator suggested be neutralizing antibodies (nAbs), which mainly block interaction between Spike protein (S) SARS-CoV-2 and host entry receptor ACE2. In this study, we aimed develop optimize conditions competitive ELISA measure serum titer, using recombinant trimeric modified have six additional proline residues (S(6P)-HexaPro) h-ACE2. results our surrogate Virus Neutralizing Assay (sVNA) were compared commercial sVNT (cPass, Nanjing GenScript Biotech Co., City, China), serially diluted sera from vaccinees, high correlation ID
Язык: Английский
Процитировано
2
Vaccines, Год журнала: 2024, Номер 12(8), С. 921 - 921
Опубликована: Авг. 16, 2024
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), emerged as a global outbreak in 2019, profoundly affecting both human health and the economy. Various vaccine modalities were developed commercialized to overcome this challenge, including inactivated vaccines, mRNA adenovirus vector-based subunit vaccines. While intramuscular vaccines induce high IgG levels, they often fail stimulate significant mucosal immunity system. We employed Newcastle virus (NDV) vector expressing spike protein of SARS-CoV-2 Beta variant (rK148/beta-S), evaluated efficacy intranasal vaccination with rK148/beta-S K18-hACE2 transgenic mice. Intranasal low dose (10
Язык: Английский
Процитировано
2
Опубликована: Май 13, 2024
Cancer patients, susceptible to severe COVID-19 outcomes, exhibit varied vaccine responses, particularly those who are receiving chemotherapy. This prospective cohort study enrolled 115 cancer and data from 91 patients received two doses of vaccines were analyzed. Blood was drawn at baseline, day 28, 6 months post-second dose for neutralizing antibody analysis. The primary outcome seroconversion rate against wild type Omicron 28. Secondary outcomes included months, factors associated with seroconversion, safety. Of the 157 screened, enrolled, 45% Seroconversion rates 28 77% 62% Omicron. Chemotherapy did not affect (p=0.789 type, p=0.597 Omicron). Vaccine positively correlated an adjusted ORR 25.86 (p=0.029) 17.38 (p
Язык: Английский
Процитировано
1
Viruses, Год журнала: 2024, Номер 16(9), С. 1409 - 1409
Опубликована: Сен. 3, 2024
Neutralizing antibodies plays a primary role in protective immunity by preventing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) from entering the cells. Therefore, characterization of antiviral is important for protection against SARS-CoV-2. In this study, neutralizing effect anti-SARS-CoV-2 S1 protein IgG, which was detected using chemiluminescence microparticle immunoassay (CMIA)-based SARS-CoV-2 IgG II Quant (Abbott, Waukegan, IL, USA) test infected and/or vaccinated individuals, investigated with surrogate virus neutralization (sVNT). total, 120 Seropositive individuals were included study. They divided into two groups: Vaccinated (
Язык: Английский
Процитировано
1
PLoS ONE, Год журнала: 2024, Номер 19(11), С. e0310781 - e0310781
Опубликована: Ноя. 7, 2024
The aim of this study was to assess the seroconversion rate and percent inhibition neutralizing antibodies against wild-type Omicron variants SARS-CoV-2 in patients with solid cancer who received two COVID-19 vaccine doses by comparing chemotherapy nonchemotherapy groups.
Язык: Английский
Процитировано
0
Vaccines, Год журнала: 2024, Номер 12(12), С. 1362 - 1362
Опубликована: Дек. 2, 2024
Background: The COVID-19 pandemic has led to the rapid development of new vaccines and methods testing vaccine-induced immunity. Despite extensive research that been conducted on level specific antibodies, less attention paid studying avidity these antibodies. serum antibodies is associated with a vaccine showing high effectiveness reflects process affinity maturation. In context against SARS-CoV-2, only limited number studies have investigated often solely focusing wild-type virus following vaccination. This study provides insights into adenovirus-based boosters. We focused effects an intranasal Salnavac booster, which compared, using single analytical platform, intramuscular Sputnik V. Methods: RBD-specific IgGs IgAs was through ELISA urea biolayer interferometry. Results: results demonstrated similar avidities were induced by both for six months post-booster. However, increase in antibody observed Delta variants, but not BA.4/5 variant. Conclusions: Collectively, our data provide maturation after SARS-CoV-2.
Язык: Английский
Процитировано
0